Recombinant Vaccines Market Opportunities Are Emerging Beyond Traditional Growth Areas
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Recombinant Vaccines Market Expected To Reach $28.07 Billion By 2030 At 12.2% CAGR
The recombinant vaccines market has seen significant growth in recent years. Its projected expansion will take it from $15.79 billion in 2025 to $17.69 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.0%. This historical growth is largely due to factors such as the successful deployment of hepatitis B recombinant vaccines, past global vaccination efforts, increased public understanding of viral diseases, a rise in immunization funding, and supportive regulatory frameworks for safer vaccine platforms.
The recombinant vaccines market size is projected to experience substantial expansion over the coming years, with an anticipated growth to $28.07 billion by 2030, at a compound annual growth rate (CAGR) of 12.2%. This anticipated growth during the forecast period is primarily driven by factors such as the increasing need for precision vaccines, the broader availability of vaccines for emerging diseases, the rise in adult booster initiatives, expanding worldwide immunization coverage, and a robust pipeline of recombinant candidates. Key developments shaping the market during this period involve an uptick in recombinant subunit vaccines, the broadening of vector-based vaccine platforms, more extensive adult immunization programs, the development of combination recombinant vaccines, and an intensified focus on long-lasting immunity.
Download A Free Sample Report For Comprehensive Market Insights:
Recombinant Vaccines Market Growth Momentum: Which Factors Are Influencing Demand?
The rising occurrence of infectious diseases is anticipated to boost the expansion of the recombinant vaccines market. Infectious diseases are illnesses caused by microorganisms like bacteria, viruses, fungi, or parasites, which can be transmitted between individuals directly or indirectly. The increase in the prevalence of these diseases stems from inadequate sanitation and hygiene, as insufficient access to clean water, proper sanitation, and effective waste disposal facilitates the easy transmission of harmful microorganisms via tainted food, water, and personal interaction, consequently heightening infection risks. Recombinant vaccines combat infectious diseases by utilizing biologically engineered genetic material from pathogens to provoke an immune response without causing sickness. For instance, in July 2024, the Australian Institute of Health and Welfare, a national agency based in Australia, reported that over 109,000 chlamydia and more than 40,000 gonorrhea notifications were the most frequently reported sexually transmitted infections in Australia in 2023, alongside over 6,400 infectious syphilis cases, underscoring the escalating incidence and persistent public health difficulties. Consequently, the growing incidence of infectious diseases is propelling the growth of the recombinant vaccines market.
#Recombinant Vaccines Market Segment Landscape And Growth Potential
The recombinant vaccines market covered in this report is segmented –
1) By Type: Subunit Vaccines; Vector-Based Vaccines
2) By Disease Indication: Human Papillomavirus (HPV); Herpes Zoster; Hepatitis B; Other Diseases
3) By Route Of Administration: Parenteral; Other Route Of Administrations
4) By End User: Pediatric; Adults
Subsegments:
1) By Subunit Vaccines: Protein Subunit Vaccines; Polysaccharide Subunit Vaccines; Conjugate Subunit Vaccines; Glycopeptide Subunit Vaccines; Recombinant Subunit Vaccines
2) By Vector-Based Vaccines: Viral Vector Vaccines; Non Viral Vector Vaccines; Replicating Vector Vaccines; Non Replicating Vector Vaccines; Bacterial Vector Vaccines
Recombinant Vaccines Market Trends Reshaping Industry Growth
Companies active in the recombinant vaccines market are concentrating on the creation of innovative vaccines, such as the recombinant 9-valent HPV vaccine, to secure a competitive advantage. This recombinant 9-valent HPV vaccine offers protection against nine types of human papillomavirus (HPV) and is produced through recombinant DNA technology in a laboratory setting, without the use of live viruses, which assists in preventing HPV-related illnesses including cervical cancer and genital warts. For instance, in August 2023, Jiangsu Recbio Technology Co. Ltd., a China-based biopharmaceutical company, moved its recombinant 9-valent HPV vaccine, REC603, through Phase III clinical follow-up, with 24-month observations still in progress. The vaccine displayed strong immunogenicity, a favorable safety profile, scalable manufacturing potential, and long-term efficacy, thereby supporting its prospects for widespread HPV prevention and commercialization.
Recombinant Vaccines Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the recombinant vaccines market are Johnson And Johnson, Merck And Co Inc., Pfizer Inc., Sanofi S. A., Novartis AG, AstraZeneca Plc, GlaxoSmithKline Plc, Mitsubishi Chemical Group Corporation, CSL Limited, Sinovac Biotech Ltd., Boehringer Ingelheim International GmbH, Zoetis Services Llc, Elanco Animal Health, BioNTech Se, Green Cross Corporation (Gc Biopharma), Bavarian Nordic A S, VBI Vaccines Inc., Vaxart Inc., Biological E Limited, Novavax Inc., Serum Institute Of India Private Limited, Vaxcyte Inc., Bharat Biotech International Limited, and Transgene S A.
Access The Complete Recombinant Vaccines Market Report:
Recombinant Vaccines Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the recombinant vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
